Pfizer Inc. (NYSE:PFE)

Reported net income attributable to Pfizer Inc. common shareholders exhibited significant fluctuation between 2021 and 2025. A substantial increase occurred from 2021 to 2022, followed by a dramatic decline in 2023, and a partial recovery in subsequent years. The adjusted net income attributable to Pfizer Inc. common shareholders mirrors this trend, though the magnitude of the changes is slightly less pronounced.

Overall Trend

From 2021 to 2022, both reported and adjusted net income increased considerably, with reported net income rising from US$21,979 million to US$31,372 million, and adjusted net income increasing from US$21,642 million to US$31,813 million. This represents a growth of approximately 42.8% and 47.2% respectively. However, 2023 witnessed a sharp decrease in both metrics. Reported net income fell to US$2,119 million, while adjusted net income decreased to US$1,890 million. A moderate recovery was observed in 2024 and 2025, with reported net income reaching US$8,031 million and US$7,771 million, and adjusted net income reaching US$7,935 million and US$7,850 million respectively.

Adjustment Impact

The difference between reported and adjusted net income remains relatively consistent across the observed period. The adjustment, related to mark-to-market changes in available-for-sale securities, typically reduces reported net income by a few hundred million US dollars annually. In 2022, the adjustment was US$531 million, while in 2023 it was US$229 million. In 2024, the adjustment was US$96 million, and in 2025 it was US$21 million. This suggests that the impact of these security valuations on net income is present but not a primary driver of the large fluctuations observed in overall profitability.

The substantial decline in net income in 2023 warrants further investigation. While the mark-to-market adjustment plays a role, the primary driver appears to be a broader shift in the company’s overall financial performance. The subsequent partial recovery in 2024 and 2025 indicates a stabilization, but the levels remain significantly below the peak observed in 2022.

The profitability ratios demonstrate significant fluctuations over the five-year period. Initial values are followed by a marked decline in 2023, with a partial recovery observed in 2024 and 2025. The adjusted ratios generally mirror the reported ratios, suggesting that adjustments related to mark-to-market available-for-sale securities have a relatively consistent impact on overall profitability metrics.

Net Profit Margin

Both the reported and adjusted net profit margins exhibit a peak in 2022 at approximately 31%. A substantial decrease is then observed in 2023, falling to 3.56% and 3.17% respectively. These margins partially recover in 2024 and 2025, stabilizing around 12.5%. The consistency between reported and adjusted values indicates that changes in the valuation of available-for-sale securities do not materially alter the overall trend in net profitability.

Return on Equity (ROE)

Similar to the net profit margin, reported and adjusted ROE values peak in 2022, reaching 32.79% and 33.26% respectively. A dramatic decline occurs in 2023, with both ratios falling below 2.5%. A modest recovery is evident in 2024 and 2025, with ROE stabilizing around 9%. The parallel movement of reported and adjusted ROE suggests that changes in equity, driven by mark-to-market adjustments, are correlated with changes in net income.

Return on Assets (ROA)

Reported and adjusted ROA follow a comparable pattern to the other ratios. Both metrics peak in 2022, at 15.91% and 16.13% respectively, before experiencing a significant drop in 2023 to below 1%. A slight improvement is seen in 2024 and 2025, with ROA remaining around 3.75%. The close alignment between reported and adjusted ROA suggests that the impact of mark-to-market adjustments on asset valuation is not a primary driver of the observed fluctuations.

Overall, the period is characterized by strong profitability in 2022, followed by a substantial downturn in 2023, and a subsequent, limited recovery in 2024 and 2025. The consistent relationship between reported and adjusted ratios suggests that the adjustments related to available-for-sale securities are not the sole cause of these fluctuations, but rather reflect broader changes in underlying business performance.

The period under review demonstrates significant fluctuations in profitability metrics. Reported net income attributable to Pfizer Inc. common shareholders peaked in 2022 at US$31,372 million before experiencing a substantial decline in subsequent years, reaching US$7,771 million by 2025. A similar pattern is observed in adjusted net income, though the magnitude of the decrease is slightly less pronounced. Correspondingly, both reported and adjusted net profit margins exhibit a marked decrease from 2022 to 2023, followed by a period of relative stabilization.

Reported Net Profit Margin

The reported net profit margin began at 26.76% in 2021, increased to a high of 31.01% in 2022, and then decreased sharply to 3.56% in 2023. A partial recovery is noted in 2024 and 2025, with margins stabilizing at 12.62% and 12.42% respectively. This suggests a significant shift in cost structure or revenue generation following 2022.

Adjusted Net Profit Margin

The adjusted net profit margin mirrors the trend of the reported margin, starting at 26.35% in 2021, peaking at 31.44% in 2022, and declining to 3.17% in 2023. Similar to the reported margin, the adjusted margin shows a modest increase in 2024 and 2025, reaching 12.47% and 12.54% respectively. The close alignment between reported and adjusted margins indicates that adjustments are not materially impacting the overall profitability picture.

The difference between reported and adjusted net income remains relatively small throughout the period, suggesting that adjustments are not masking significant underlying accounting discrepancies. The substantial drop in both reported and adjusted net profit margins from 2022 to 2023 warrants further investigation to determine the underlying drivers, such as changes in revenue, cost of goods sold, or operating expenses. The stabilization of margins in 2024 and 2025 may indicate that these factors have begun to normalize, but continued monitoring is recommended.

The period under review demonstrates significant fluctuations in reported and adjusted net income attributable to Pfizer Inc. common shareholders, consequently impacting return on equity (ROE) metrics. A substantial increase in net income occurred between 2021 and 2022, followed by a marked decline in subsequent years. This pattern is reflected in both reported and adjusted ROE values.

Net Income Trends

Reported net income attributable to Pfizer Inc. common shareholders peaked at US$31,372 million in 2022, representing a considerable increase from US$21,979 million in 2021. However, this was followed by a dramatic decrease to US$2,119 million in 2023, with a partial recovery to US$8,031 million in 2024 and remaining relatively stable at US$7,771 million in 2025. Adjusted net income mirrors this trend, exhibiting a similar peak in 2022 and subsequent decline, though the magnitude of the decrease is less pronounced.

Reported ROE Analysis

Reported ROE followed the trend of net income. It increased from 28.47% in 2021 to 32.79% in 2022, then experienced a substantial drop to 2.38% in 2023. A recovery was observed in 2024 and 2025, reaching 9.11% and 8.99% respectively, though these values remain significantly below the 2022 peak.

Adjusted ROE Analysis

Adjusted ROE exhibited a similar pattern to reported ROE. It rose from 28.03% in 2021 to 33.26% in 2022, then declined sharply to 2.12% in 2023. Subsequent years showed a modest recovery, with adjusted ROE reaching 9.00% in 2024 and 9.08% in 2025. The difference between reported and adjusted ROE remains consistently small across all periods.

The substantial decline in both reported and adjusted ROE from 2022 to 2023 warrants further investigation. While a partial recovery is evident in 2024 and 2025, the values do not return to the levels observed in 2021 and 2022. The consistency between reported and adjusted ROE suggests that the fluctuations are driven by underlying changes in net income rather than accounting adjustments.

The period under review demonstrates significant fluctuations in reported and adjusted net income, consequently impacting return on assets. A substantial increase in both reported and adjusted net income is evident from 2021 to 2022, followed by a marked decline in 2023, with a partial recovery in 2024 and 2025. This pattern is mirrored in the observed return on assets figures.

Reported Return on Assets (ROA)

Reported ROA increased from 12.11% in 2021 to 15.91% in 2022, aligning with the rise in reported net income. However, 2023 witnessed a dramatic decrease to 0.94%, reflecting the substantial reduction in reported net income for that year. A modest recovery occurred in 2024 (3.76%) and remained relatively stable in 2025 (3.73%).

Adjusted Return on Assets (ROA)

The trend in adjusted ROA closely follows that of the reported ROA. It rose from 11.93% in 2021 to 16.13% in 2022, then fell sharply to 0.83% in 2023. Similar to the reported ROA, adjusted ROA showed a slight improvement in 2024 (3.72%) and a further, albeit small, increase in 2025 (3.77%).

Relationship between Reported and Adjusted ROA

The difference between reported and adjusted ROA remains consistently small across all years examined. This suggests that adjustments to net income have a limited impact on the overall ROA calculation. The values are very close, indicating that the adjustments made are not materially altering the profitability picture as measured by ROA.

Overall Trend

The most prominent feature of the period is the volatility in profitability, as reflected by ROA. The peak in 2022 is followed by a significant downturn in 2023, and a subsequent leveling off at a considerably lower level in 2024 and 2025. This suggests a potential shift in underlying business conditions or a non-recurring boost to earnings in 2022. Further investigation into the factors driving the 2023 decline would be warranted.